Soliris (eculizumab) Letter of Medical Necessity
Soliris (eculizumab) carries one of the highest annual costs in pharmacy ($500K+) and faces uniformly strict prior authorization. Many payers now prefer Ultomiris (ravulizumab) due to less frequent dosing — Letters of Medical Necessity must address that step-therapy preference.
FDA-Approved Indications
- ● paroxysmal nocturnal hemoglobinuria (PNH)
- ● atypical hemolytic uremic syndrome (aHUS)
- ● generalized myasthenia gravis (anti-AChR antibody positive)
- ● neuromyelitis optica spectrum disorder (anti-AQP4 antibody positive)
Why Soliris Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Meningococcal vaccination (serogroups A, C, W, Y, and B) not documented ≥2 weeks prior
- 2. Diagnostic confirmation incomplete (flow cytometry for PNH, ADAMTS13 for aHUS exclusion)
- 3. Antibody status not documented (anti-AChR for gMG, anti-AQP4 for NMOSD)
- 4. Ultomiris (longer-acting C5 inhibitor) preferred on formulary
- 5. REMS enrollment incomplete
What to Include in a Soliris Letter of Medical Necessity
Document diagnosis with confirmatory testing (high-sensitivity flow cytometry for PNH clone size, ADAMTS13 activity to exclude TTP for aHUS, anti-AChR or anti-AQP4 titers, single-fiber EMG for gMG), severity metrics, meningococcal vaccination dates and serogroups, REMS enrollment, and clinical rationale for Soliris over Ultomiris if applicable (e.g., insurance coverage, prior tolerability).
Key clinical evidence to cite:
- ✓ TRIUMPH and SHEPHERD trials (PNH) — transfusion independence and reduced hemolysis
- ✓ C08-002 trial (aHUS) — TMA event-free status
- ✓ REGAIN trial (gMG) — improved MG-ADL scores
- ✓ PREVENT trial (NMOSD) — reduced relapse risk
Relevant guidelines:
- 📖 ASH 2021 PNH Guidelines
- 📖 IPNA aHUS Guidelines
- 📖 MGFA gMG Treatment Recommendations
- 📖 NMO-NMOSD Consensus Diagnostic Criteria
Soliris Prior Authorization Criteria
Standard criteria across major US payers for Soliris. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Meningococcal vaccination (serogroups A, C, W, Y, and B) not documented ≥2 weeks prior
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Soliris
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Soliris Prior Authorization FAQ
Why was my Soliris prior authorization denied?
The most common denial reasons for Soliris are: Meningococcal vaccination (serogroups A, C, W, Y, and B) not documented ≥2 weeks prior; Diagnostic confirmation incomplete (flow cytometry for PNH, ADAMTS13 for aHUS exclusion); Antibody status not documented (anti-AChR for gMG, anti-AQP4 for NMOSD); Ultomiris (longer-acting C5 inhibitor) preferred on formulary; REMS enrollment incomplete.
What should a Soliris Letter of Medical Necessity include?
Document diagnosis with confirmatory testing (high-sensitivity flow cytometry for PNH clone size, ADAMTS13 activity to exclude TTP for aHUS, anti-AChR or anti-AQP4 titers, single-fiber EMG for gMG), severity metrics, meningococcal vaccination dates and serogroups, REMS enrollment, and clinical rationale for Soliris over Ultomiris if applicable (e.g., insurance coverage, prior tolerability).
Which payers cover Soliris?
Soliris is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.